192 related articles for article (PubMed ID: 30318453)
1. The spectrum of type III hyperlipoproteinemia.
Sniderman AD; de Graaf J; Thanassoulis G; Tremblay AJ; Martin SS; Couture P
J Clin Lipidol; 2018; 12(6):1383-1389. PubMed ID: 30318453
[TBL] [Abstract][Full Text] [Related]
2. Hypertriglyceridemic hyperapoB in type 2 diabetes.
Sniderman AD; Lamarche B; Tilley J; Seccombe D; Frohlich J
Diabetes Care; 2002 Mar; 25(3):579-82. PubMed ID: 11874951
[TBL] [Abstract][Full Text] [Related]
3. Ratio of remnant-like particle-cholesterol to serum total triglycerides is an effective alternative to ultracentrifugal and electrophoretic methods in the diagnosis of familial type III hyperlipoproteinemia.
Wang T; Nakajima K; Leary ET; Warnick GR; Cohn JS; Hopkins PN; Wu LL; Cilla DD; Zhong J; Havel RJ
Clin Chem; 1999 Nov; 45(11):1981-7. PubMed ID: 10545069
[TBL] [Abstract][Full Text] [Related]
4. Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein.
Sniderman AD; Tremblay A; De Graaf J; Couture P
J Clin Lipidol; 2012; 6(5):427-33. PubMed ID: 23009778
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the chylomicron-TG to VLDL-TG ratio for type I hyperlipoproteinemia diagnostic.
Rioja J; Ariza MJ; García-Casares N; Coca-Prieto I; Arrobas T; Muñiz-Grijalvo O; Mangas A; Ibarretxe D; Sánchez-Chaparro MÁ; Valdivielso P
Eur J Clin Invest; 2020 Dec; 50(12):e13345. PubMed ID: 32649781
[TBL] [Abstract][Full Text] [Related]
6. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia.
Campos H; Perlov D; Khoo C; Sacks FM
J Lipid Res; 2001 Aug; 42(8):1239-49. PubMed ID: 11483625
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
8. Postprandial remnant-like lipoproteins in hypertriglyceridemia.
Ooi TC; Cousins M; Ooi DS; Steiner G; Uffelman KD; Nakajima K; Simo IE
J Clin Endocrinol Metab; 2001 Jul; 86(7):3134-42. PubMed ID: 11443178
[TBL] [Abstract][Full Text] [Related]
9. Differences in postprandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease.
Karpe F; Hellénius ML; Hamsten A
Metabolism; 1999 Mar; 48(3):301-7. PubMed ID: 10094104
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Non-HDL Cholesterol to Apolipoprotein B Ratio as a Screening Test for Dysbetalipoproteinemia.
Boot CS; Middling E; Allen J; Neely RDG
Clin Chem; 2019 Feb; 65(2):313-320. PubMed ID: 30538126
[TBL] [Abstract][Full Text] [Related]
11. Fish oil supplementation reduces beta-very low density lipoprotein in type III dysbetalipoproteinemia.
Dallongeville J; Boulet L; Davignon J; Lussier-Cacan S
Arterioscler Thromb; 1991; 11(4):864-71. PubMed ID: 2065040
[TBL] [Abstract][Full Text] [Related]
12. Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects.
Norioka M; Suzuki M; Ryomoto K; Ikebuchi M; Harano Y
J Atheroscler Thromb; 2000; 7(4):198-202. PubMed ID: 11521682
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins.
Ishigami M; Yamashita S; Sakai N; Hirano K; Hiraoka H; Nakamura T; Matsuzawa Y
Atherosclerosis; 2003 Jun; 168(2):359-66. PubMed ID: 12801620
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B.
Sniderman A; Tremblay A; Bergeron J; Gagné C; Couture P
J Clin Lipidol; 2007 Aug; 1(4):256-63. PubMed ID: 21291689
[TBL] [Abstract][Full Text] [Related]
15. Relation between RLP-triglyceride to RLP-cholesterol ratio and particle size distribution in RLP-cholesterol profiles by HPLC.
Okazaki M; Usui S; Tada N; Nakano T; Nakajima K
Clin Chim Acta; 2000 Jun; 296(1-2):135-49. PubMed ID: 10807977
[TBL] [Abstract][Full Text] [Related]
16. Serum remnant lipoprotein cholesterol/triglyceride ratio as an index for screening familial type III hyperlipidaemia.
Nakajima K; Daimon M; Kamiyama K; Takanashi K; Suzuki Y; Watanabe M; Kubono K; Saniabadi AR; Takashima S; Sakurabayashi I
Ann Clin Biochem; 2007 Jul; 44(Pt 4):353-9. PubMed ID: 17663088
[TBL] [Abstract][Full Text] [Related]
17. Detailed analysis of serum lipids and lipoproteins from Japanese type III hyperlipoproteinemia with apolipoprotein E2/2 phenotype.
Todo Y; Kobayashi J; Higashikata T; Kawashiri M; Nohara A; Inazu A; Koizumi J; Mabuchi H
Clin Chim Acta; 2004 Oct; 348(1-2):35-40. PubMed ID: 15369733
[TBL] [Abstract][Full Text] [Related]
18. Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects.
Marcoux C; Tremblay M; Fredenrich A; Jacques H; Krimbou L; Nakajima K; Davignon J; Cohn JS
Atherosclerosis; 1998 Jul; 139(1):161-71. PubMed ID: 9699904
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein B: the Rosetta Stone of lipidology.
Glavinovic T; Sniderman AD
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):90-96. PubMed ID: 33229928
[TBL] [Abstract][Full Text] [Related]
20. Importance of the triglyceride level in identifying patients with a Type III Hyperlipoproteinemia phenotype using the ApoB algorithm.
Varghese B; Park J; Chew E; Sajja A; Brownstein A; Pallazola VA; Sathiyakumar V; Jones SR; Sniderman AD; Martin SS
J Clin Lipidol; 2021; 15(1):104-115.e9. PubMed ID: 33189625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
